Abstract 594P
Background
MET alteration, as promising rare target, plays the key role in the development of NSCLC. However, the treatment pattern and efficacy for Chinese NSCLC patients (pts) with MET alteration in real-world setting is limited. Here, we report the treatment pattern and clinical outcome in Chinese NSCLC pts with MET alteration.
Methods
We performed a retrospective, multicenter study in NSCLC pts with MET alteration between Jul. 2021 and Sep. 2022 in China. Patient characteristics, gene profile, and treatment pattern were collected. The objective response rate (ORR) and time to treatment failure (TTF) were analyzed.
Results
202 NSCLC pts with MET alteration were collected. 117 MET exon 14 skipping mutation (MET ex14m) and MET amplification (amp) (MET NGS GCN≥3.5) pts with subsequent efficacy assessment and follow-up data were included for analysis. The ORR of pts with MET ex14m received 1L savolitinib (savo mono), other MET inhibitor (METi) and chemotherapy (chemo)-based regimen were 56.3%, 16.7%, 36.3%, respectively. The ORR of pts with de novo MET amp received savo, other METi, and chemo-based regimen as 1st-line therapy were 66.7%, 0, 20%, respectively. The ORR of post EGFR/ALK-TKI resistance pts with MET amp (resistant MET amp) received savo mono, savo plus osimertinib (osi), other METi and chemo-based regimen were 12.5%, 43.8%, 0, 14.2%, respectively. (Table) Median TTF of 1L savo mono in pts with MET ex14m was 12.6months and median TTF of savo plus osi in pts with resistant MET amp was 11.3 months. Savo discontinuation due to adverse events occurred in MET ex14m, de novo MET amp and resistant MET amp pts were 18.7%, 33.3%, and 7%, respectively. The safety profile of savo were similar to previously reported data. Table: 594P
The ORR result in the analysis
| MET ex14m (n=44) | De novo MET amp (n=16) | Resistant MET amp (n=57) | |||||
| n | ORR | n | ORR | n | ORR | ||
| 1L | Savo | 16 | 56.3% | 3 | 66% | NA | |
| Other METi | 6 | 16.7% | 3 | 0% | |||
| Chemo | 22 | 36.3% | 10 | 20% | |||
| 2L+ | Savo | 14 | 42.8% | 2 | 50% | 8 | 12.5% |
| Savo+osi | 2 | 50% | 2 | 50% | 32 | 43.8% | |
| Other METi | 3 | 0 | 0 | NA | 3 | 0 | |
| Chemo | 23 | 26.1% | 14 | 28.5% | 14 | 14.2% |
Conclusions
The real-world analysis results showed the promising clinical benefit of savo in NSCLC pts with MET alterations and the acceptable safety. Follow-up of these pts are still ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract